Capitalizing on Success
Industry investments indicate increasing trust in the newest modalities, including mRNA approaches.
High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com
As of mid-October 2023, there were 9342 clinical trial studies targeting COVID-19 (1). This is alongside 12,086 patents that relate to COVID-19 (2). Messenger RNA (mRNA) clinical trials, however, stand at only 483, with 112 related patents. mRNA was the talk of the industry during October 2023, as Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine for their work in mRNA vaccines against COVID-19.
In an interview with Pharmaceutical Technology®, Laks Pernenkil, Principal and Practice Leader, US Life Sciences, Deloitte, pointed to “an emphasis coming out of the pandemic on supply resilience … with all the ups and downs around the supply of raw materials, there has been significant focus on ensuring patients are not affected by supply shortages, part of the anxiety has manifested around inflation [rising costs] of raw materials.” Pernenkil also drew attention to increased digitalization as improving process design, supply performance, and eventually, profits (3).
At the other end of the spectrum, discovering new types of drugs and therapies, the top five pharmaceutical companies’ investments in R&D in 2022 were Roche with $14.78 Billion, J&J $14.14 billion, Pfizer $12.38 billion, Merck $11.84, and BMS $10.02 billion, ranging between 15% to 30% of income (4). Such investment speaks of self-confidence and perhaps aligns with increasing trust in the newest modalities, including mRNA approaches.
References
- NIH. https://clinicaltrials.gov. Clinical trials.gov (accessed Oct. 12, 2023).
- World Health Organization, WHO’s Covid-19 Response Timeline (accessed Oct. 12, 2023).
- Playter, G. The Era of Digital Data in Bio/Pharma Manufacturing. PharmTech.com. Oct. 9, 2023.
- Statista. Leading 50 Global Pharmaceutical Companies by Prescription Sales and R&D Spending in 2022. Statista (accessed Oct. 12, 2023).
Article details
BioPharm International
Vol. 36, No. 11
November 2023
Page: 6
Citation
When referring to this article, please cite it as Hennessy, M. Capitalizing on Success. BioPharm International 2023 36 (11).
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
